(Q46495924)

22 December 2017

title

Urinary osteocalcin and other markers of bone metabolism: the effect of risedronate therapy (English)

1 reference

22 December 2017

1 reference

2

1 reference

22 December 2017

author name string

Jaanika Kumm

1

1 reference

22 December 2017

Kadri Rohtla

3

1 reference

22 December 2017

Kalervo Vaananen

4

1 reference

22 December 2017

Agu Tamm

5

1 reference

22 December 2017

publication date

1 January 2008

1 reference

22 December 2017

Scandinavian Journal of Clinical and Laboratory Investigation

number of pages

5

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

22 December 2017

volume

68

1 reference

22 December 2017

issue

6

1 reference

22 December 2017

page(s)

459-463

1 reference

22 December 2017

Osteocalcin: diagnostic methods and clinical applications

cites work

1 reference

https://api.crossref.org/works/10.1080%2F00365510701832237

Release of intact and fragmented osteocalcin molecules from bone matrix during bone resorption in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510701832237

Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510701832237

Metabolism of osteocalcin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510701832237

Multiple osteocalcin fragments in human urine and serum as detected by a midmolecule osteocalcin radioimmunoassay

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510701832237

Identification of peptide fragments generated by digestion of bovine and human osteocalcin with the lysosomal proteinases cathepsin B, D, L, H, and S

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510701832237

A urine midmolecule osteocalcin assay shows higher discriminatory power than a serum midmolecule osteocalcin assay during short-term alendronate treatment of osteoporotic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510701832237

Identification of novel proteolytic forms of osteocalcin in human urine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510701832237

Urinary osteocalcin is a useful marker for monitoring the effect of alendronate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510701832237

Efficacy of risedronate on clinical vertebral fractures within six months.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510701832237

Review of treatment modalities for postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510701832237

Urinary osteocalcin as a marker of bone metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510701832237

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510701832237

Serum tartrate-resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral density.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510701832237

The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510701832237

Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510701832237

10.1080/00365510701832237

21 January 2018

Identifiers

DOI

1 reference

22 December 2017

1 reference

22 December 2017